chronic
obstruct
pulmonari
diseas
copd
diseas
high
preval
substanti
associ
econom
burden
signific
determin
qualiti
life
longterm
surviv
health
care
cost
acut
exacerb
copd
acut
exacerb
provok
respiratori
virus
alter
airway
microbiom
environment
factor
current
treatment
option
limit
order
develop
specif
therapeut
measur
import
understand
acut
exacerb
evolv
review
focus
pathophysiolog
stabl
exacerb
copd
high
preval
substanti
associ
econom
burden
set
chronic
obstruct
pulmonari
diseas
copd
apart
respiratori
diseas
worldwid
million
peopl
estim
world
health
organ
copd
estim
preval
diseas
differ
countri
rang
china
preval
copd
estim
recent
studi
sixth
lead
caus
death
copd
rank
among
top
three
lead
caus
death
worldwid
million
death
mortal
rate
diseas
surpass
ischem
heart
diseas
stroke
fig
furthermor
world
health
organ
estim
overwhelm
major
almost
copdassoci
death
occur
develop
countri
due
insuffici
prevent
control
estim
preval
copd
increas
within
next
year
mortal
remain
current
rate
copd
substanti
burden
patient
health
care
system
patient
especi
sever
diseas
limit
daili
activ
dyspnoea
cough
fatigu
constant
handicap
worsen
acut
exacerb
diseas
copd
exacerb
deterior
patient
qualiti
life
surviv
signific
proport
patient
copd
experi
frequent
exacerb
frequent
exacerb
frequent
exacerb
associ
increas
likelihood
copdassoci
death
furthermor
copd
exacerb
signific
contributor
copdassoci
health
care
cost
mostli
due
hospit
thu
cost
copd
hospit
estim
billion
usa
averag
cost
hospit
per
patient
china
cost
inpati
care
acut
exacerb
copd
also
estim
high
given
copd
exacerb
signific
contributor
morbid
mortal
associ
diseas
caus
substanti
financi
cost
mainli
due
hospit
crucial
better
understand
factor
lead
copd
exacerb
abl
develop
effect
measur
prevent
andor
treat
exacerb
present
review
focu
current
understand
pathophysiolog
copd
exacerb
current
potenti
prevent
therapeut
measur
global
initi
chronic
obstruct
lung
diseas
gold
defin
copd
diseas
usual
progress
associ
enhanc
chronic
inflammatori
respons
airway
lung
noxiou
particl
gase
noxiou
particl
gase
inhal
cigarett
smoke
smoke
burn
biomass
fuel
latter
relev
lowincom
countri
anatom
abnorm
process
airway
patient
copd
develop
poorli
revers
irrevers
airway
obstruct
emphysema
ruptur
inner
wall
alveolar
sac
creation
larger
air
space
trap
air
combin
diseas
frequent
accompani
mucu
hypersecret
lead
product
cough
may
impair
bacteri
clearanc
abnorm
result
direct
damag
effect
inhal
particl
gase
subsequ
cellular
inflammatori
process
airway
inflamm
airway
patient
excess
persist
even
smoke
cessat
cellular
inflamm
character
excess
number
macrophag
b
lymphocyt
neutrophil
airway
lumen
airway
epitheli
cell
also
promin
involv
perpetu
amplif
airway
inflamm
copd
demonstr
proinflammatori
phenotyp
basal
cultur
condit
vitro
experi
airway
epitheli
cell
macrophag
cell
constantli
present
airway
probabl
first
respond
exposur
cigarett
smoke
smoke
biomass
fuel
cigarett
smoke
contain
compound
includ
carcinogen
oxid
toxic
metal
even
bacteri
endotoxin
compound
shown
cell
anim
studi
caus
inflammatori
respons
cell
apoptosi
necrosi
dysregul
innat
immun
thu
numer
studi
demonstr
cigarett
smoke
stimul
product
inflammatori
chemokin
airway
epitheli
cell
said
chemokin
attract
haemopoet
inflammatori
cell
eg
neutrophil
normal
present
airway
capabl
caus
extens
damag
effect
plausibl
inflammatori
process
initi
smoke
inhal
perpetu
amplifi
respons
cell
resid
airway
eg
airway
epitheli
cell
macrophag
lymphocyt
fibroblast
biomass
one
refer
organ
materi
wood
charcoal
dri
anim
dung
fuel
etc
use
cook
heat
dwell
biomass
combust
effici
lower
energi
sourc
typic
use
western
world
eg
coal
natur
ga
burn
biomass
releas
gase
particul
matter
includ
carbon
monoxid
pollut
oxid
cancerogen
etc
exert
damag
effect
airway
cell
similar
cigarett
smoke
possibl
damag
effect
especi
extens
suscept
individu
demonstr
fact
smoker
develop
copd
therefor
besid
exposur
damag
compound
cigarett
biofuel
smoke
may
also
take
addit
environment
genet
factor
develop
copd
patient
copd
often
harbor
increas
number
commens
pathogen
microorgan
airway
total
popul
microorgan
resid
specif
area
eg
airway
call
microbiom
studi
copd
microbiom
recent
commenc
therefor
present
limit
knowledg
potenti
microbiom
abnorm
tradit
microorgan
identifi
via
cultur
led
believ
normal
human
airway
steril
howev
newer
microbiom
studi
complement
tradit
cultur
techniqu
molecular
biolog
tool
pcr
sequenc
demonstr
even
healthi
individu
harbor
nonpathogen
microorgan
airway
contrast
patient
copd
demonstr
either
elev
number
microorgan
found
healthi
individu
microorgan
typic
present
healthi
airway
microbiom
among
differ
microorgan
typic
copd
airway
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
sever
patient
pseudomona
aeruginosa
tabl
suspect
alter
microbiom
may
also
signific
contributor
fig
top
caus
death
worldwid
world
health
care
data
caus
death
shown
percentag
copdassoci
death
account
worldwid
make
copd
among
top
three
caus
death
caus
death
show
without
label
lower
respiratori
infect
lung
cancer
hivaid
diabet
mellitu
diarrheal
diseas
road
injuri
hypertens
heart
diseas
caus
account
death
worldwid
perpetu
amplif
airway
inflamm
copd
past
atop
asthma
seen
disord
differ
copd
research
emphas
eosinophildriven
inflammatori
mechan
atop
asthma
neutrophildriven
inflamm
copd
howev
increasingli
recogn
asthma
copd
may
part
long
continuum
respiratori
diseas
mani
disord
atop
asthma
smoker
allergi
patient
copd
latter
patient
inflammatori
process
airway
may
associ
eosinophilia
nonsmok
also
develop
copd
diseas
develop
unclear
pathogenesi
patient
may
involv
genet
andor
environment
factor
includ
secondhand
exposur
cigarett
smoke
genet
factor
predispos
copd
reveal
possibl
due
multigenet
natur
abnorm
airway
eg
antioxid
inflammatori
gene
gene
encod
proteolyt
enzym
etc
howev
mutat
gene
encod
antitrypsin
caus
patholog
abnorm
lung
similar
emphysema
howev
genet
disord
typic
classifi
separ
typic
copd
consensu
definit
acut
exacerb
copd
follow
acut
event
character
worsen
patient
respiratori
symptom
beyond
normal
daytoday
variat
lead
chang
medic
note
copd
exacerb
neg
affect
qualiti
life
patient
exacerb
also
substanti
increas
risk
prematur
death
caus
substanti
financi
burden
health
care
system
due
hospit
need
special
care
typic
provok
factor
copd
exacerb
bacteri
viral
infect
discuss
patient
copd
report
harbor
divers
bacteria
often
includ
opportunist
microorgan
p
aeruginosa
exacerb
number
bacteria
commonli
h
influenza
increas
mani
patient
may
outgrowth
exist
strain
acquisit
new
one
bacteriadriven
genesi
mani
copd
exacerb
especi
increas
sputum
purul
confirm
clinic
efficaci
antibiot
studi
demonstr
acut
exacerb
may
associ
acquisit
new
bacteri
strain
patient
specif
antibodi
observ
support
etiolog
role
bacteri
infect
acut
exacerb
copd
lead
acquisit
new
strain
outgrowth
exist
strain
recent
research
data
strongli
suggest
major
copd
exacerb
associ
upper
respiratori
viral
infect
first
respiratori
virus
detect
upper
lower
airway
secret
patient
copd
signific
number
acut
exacerb
second
experiment
viru
infect
patient
copd
demonstr
subsequ
bacteri
outgrowth
confirm
caus
link
upper
respiratori
viru
infect
subsequ
bacteri
infect
acut
exacerb
copd
estim
viral
bacteri
infect
combin
respons
two
third
three
quarter
copd
exacerb
role
respiratori
virus
pathogen
provok
major
increasingli
recogn
owe
clinic
avail
multiplex
pcr
detect
respiratori
virus
greatli
facilit
recent
year
respiratori
virus
commonli
detect
acut
exacerb
copd
human
rhinovirus
respiratori
syncyti
viru
influenza
viru
virus
detect
less
frequent
tabl
among
virus
vaccin
avail
influenza
viru
monoclon
antibodi
respiratori
syncyti
viru
palivizumab
influenza
vaccin
routin
use
patient
copd
discuss
widespread
influenza
vaccin
western
countri
decreas
detect
viru
copd
exacerb
cost
palivizumab
high
author
review
awar
use
drug
copd
neither
vaccin
monoclon
antibodi
avail
human
rhinovirus
pivot
role
human
rhinovirus
copd
exacerb
demonstr
epidemiolog
studi
studi
experiment
infect
specif
shown
inocul
patient
copd
lowdos
rhinoviru
lead
lower
airway
symptom
typic
copd
exacerb
breathless
cough
increas
mucu
product
etc
well
secondari
bacteri
infect
furthermor
peak
rhinoviru
load
lower
airway
secret
preced
rise
bacteri
load
confirm
anecdot
evid
report
mani
patient
copd
upper
respiratori
viral
infect
common
cold
sever
day
develop
acut
exacerb
diseas
furthermor
northern
region
number
acut
exacerb
copd
peak
fall
winter
month
also
month
highest
preval
upper
respiratori
viru
infect
therefor
effort
aim
develop
effect
antivir
measur
also
human
rhinoviru
prevent
secondari
bacteri
infect
sinc
appear
precipit
copd
exacerb
onethird
copd
exacerb
provok
factor
bacteri
viral
infect
could
allergi
patient
preexist
allergi
environment
factor
stress
intrins
factor
environment
factor
air
pollut
especi
relev
citi
larg
industri
base
mani
china
intrins
factor
may
play
role
suscept
copd
individu
frequent
exacerb
socal
frequent
exacerb
although
also
possibl
patient
prone
viral
bacteri
infect
furthermor
poor
patient
complianc
therapi
stabl
diseas
shown
risk
factor
exacerb
current
armamentarium
prophylact
therapeut
measur
effect
control
copd
exacerb
limit
mention
vaccin
current
avail
influenza
viru
addit
vaccin
endem
influenza
strain
produc
empir
basi
follow
outbreak
south
far
east
asia
therefor
usual
lag
time
sever
month
identif
viru
strain
potenti
caus
influenza
endem
product
vaccin
avail
vaccin
gener
popul
vulner
subpopul
includ
patient
copd
due
multipl
human
rhinoviru
viru
caus
major
upper
respiratori
viral
infect
univers
vaccin
yet
come
antivir
antiinfluenza
drug
amantadin
may
effect
extens
advers
effect
current
guidelin
copd
provid
recommend
use
antivir
antiinfluenza
drug
clinic
trial
augment
therapi
aerosol
interferonb
asthma
interferonb
antivir
cytokin
may
potenti
facilit
viru
clearanc
lower
airway
patient
copd
howev
clinic
studi
done
date
test
antivir
efficaci
safeti
interferonb
patient
regard
alter
microbiom
pneumococc
vaccin
boost
immun
pneumonia
vaccin
current
recommend
patient
copd
still
lack
larg
random
control
trial
object
assess
benefit
pneumococc
vaccin
also
oral
vaccin
h
influenza
evid
efficaci
reduc
number
sever
copd
exacerb
mix
current
guidelin
copd
identifi
three
major
class
pharmacolog
treatment
shortact
bronchodil
system
corticosteroid
antibiot
along
support
therapi
oxygen
therapi
noninvas
invas
mechan
ventil
commonli
use
less
proven
efficaci
curb
acut
exacerb
copd
guidelin
provid
stepwis
recommend
use
pharmacolog
measur
copd
exacerb
guidelin
recommend
follow
pharmacolog
treatment
earli
outpati
rehabilit
therapi
prevent
subsequ
exacerb
exacerb
copd
often
aggrav
comorbid
common
patient
eg
ischem
heart
diseas
hypertens
pulmonari
hypertens
heart
failur
etc
therefor
condit
also
requir
medic
attent
treatment
acut
exacerb
copd
stabl
diseas
copd
guidelin
recommend
treat
comorbid
per
treatment
practic
patient
without
copd
current
intern
guidelin
specif
focus
manag
comorbid
copd
exacerb
note
though
copd
exacerb
comorbid
appear
influenc
thu
patient
copd
metabol
syndrom
common
comorbid
copd
report
frequent
acut
exacerb
copd
vice
versa
osteoporosi
sever
patient
copd
frequent
exacerb
therefor
effect
manag
comorbid
copd
improv
overal
patient
wellb
contribut
prevent
exacerb
acut
exacerb
copd
impos
substanti
burden
patient
health
care
system
lead
increas
risk
mortal
viral
infect
often
precipit
secondari
bacteri
infect
viral
bacteri
infect
recogn
provok
factor
great
major
acut
exacerb
copd
newer
therapi
need
effect
control
viral
bacteri
infect
prevent
copd
exacerb
